Eisai Gains Access to Forma's Drug Screening Technology

In return for access to Forma's compound library and cell-based screening platforms, Eisai will pay $20 million upfront and in committed funding over three years, plus potential milestone and royalty payments.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories